An under-$10 stock in the biotechnology and drugs complex that looks ready to trigger a near-term breakout trade is
(GALE - Get Report), which is focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. This stock is off to a monster so far in 2012, with shares up over 240%.
If you take a look at the chart for Galena Biopharma, you'll see that this stock has been trading range bound for the last three months, between $1.04 on the downside and $1.92 on the upside. This stock recently has started to move back above its 50-day
moving average of $1.41 a share, and it's been finding support near $1.50 a share. Traders should now keep an eye on GALE for a potential major breakout trade if this stock can take out the upper-end of its recent range with volume.
>>Hot Biotech Stocks Traded by Hedge Funds
Market players should consider long-biased trades in GALE if it can manage to trigger a break out above some near-term overhead resistance at $1.80 to $1.92 a share with
. Look for volume on a sustained move or close above those levels that register near or above its three-month average action of 2.1 million shares. If we get that action soon, then GALE could potentially make a massive move back towards its March resistance levels at $2.45 to $3.54 a share.
If you're in the bull camp on GALE, then one could look to buy this stock off any weakness and simply use a stop right below its 50-day moving average of $1.41 a share. If you get long off weakness, then look to add to that position once GALE blasts through $1.80 to $1.92 a share with heavy volume. You could also just buy off strength once it takes out those levels with volume, and simply use a stop a few percentage points below $1.80 a share.
Make note that the current short interest as a percentage of the float for GALE is pretty high at 7.5%. This stock is an excellent candidate for a short-squeeze play if it triggers that breakout soon.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts